TGFB1 and neoplasm: Finally, new approaches to interfere not only the TGF-β canonical, but also the non-canonical pathways must be developed in the next future, as previously mentioned, the switch from tumor-suppressive to pro-oncogenic TGF-β actions could be directed by its crosstalk with Receptor Tyrosine Kinases, in particular, EGFR.